China backers help bankroll a $100M mega-round as an influential antibody engineer readies trials
Kymab turned to some marquee names in the UK and the US for the money needed to establish the company as a high-profile player in the world of antibody customization over the past 6 years. But now the game plan for the next three years will be underwritten by an expanded syndicate that includes two new players based in China, extending its network of backers into a global loop.
The biotech has unveiled a whopping $100 million round led by ORI Healthcare Fund — founded by Simone (Hong Fang) Song, the former chief of Goldman Sachs’ Healthcare Fund in China — and the manufacturer Shenzhen Hepalink Pharmaceutical Company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.